<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H1EB415E38E3447B29D9A246FDD79E4B1" public-private="public">
	<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>111th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3188</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20090713">July 13, 2009</action-date>
			<action-desc><sponsor name-id="G000550">Mr. Gingrey of
			 Georgia</sponsor> (for himself, <cosponsor name-id="B001243">Mrs.
			 Blackburn</cosponsor>, <cosponsor name-id="L000566">Mr. Latta</cosponsor>,
			 <cosponsor name-id="M001158">Mr. Marchant</cosponsor>,
			 <cosponsor name-id="A000358">Mr. Akin</cosponsor>, <cosponsor name-id="B000208">Mr. Bartlett</cosponsor>, <cosponsor name-id="P000373">Mr.
			 Pitts</cosponsor>, <cosponsor name-id="B001239">Mr. Barrett of South
			 Carolina</cosponsor>, <cosponsor name-id="P000587">Mr. Pence</cosponsor>,
			 <cosponsor name-id="P000599">Mr. Posey</cosponsor>,
			 <cosponsor name-id="H001036">Mr. Hensarling</cosponsor>, and
			 <cosponsor name-id="B000755">Mr. Brady of Texas</cosponsor>) introduced the
			 following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To prohibit Federal funding or other assistance for
		  mandatory human papillomavirus (HPV) vaccination programs.</official-title>
	</form>
	<legis-body id="H1618F1052A2543B4958874B6DA7CAF92" style="OLC">
		<section id="H66AA14462FBE4F7A87DAA72423BBFA3F" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the
			 <quote><short-title>Parental Right to Decide Protection
			 Act</short-title></quote>.</text>
		</section><section id="H6D2F552ECAE3492D88439A239BAEE139"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">The Congress finds as follows:</text>
			<paragraph id="H725AF4E1585C4BEDBA07949A59F286EF"><enum>(1)</enum><text>HPV, the human
			 papillomavirus, is the most common sexually transmitted infection in the United
			 States. HPV types 16 and 18 cause about 70 percent of cervical cancers. The
			 Centers for Disease Control and Prevention estimates that about 6,200,000
			 Americans become infected with HPV each year and that over half of all sexually
			 active men and women become infected at some time in their lives. On average,
			 there are 9,710 new cases of cervical cancer and 3,700 deaths attributed to it
			 in the United States each year.</text>
			</paragraph><paragraph id="H867C1E2B254243FF838900724EBEA878"><enum>(2)</enum><text>Early detection is
			 the key to diagnosing and curing cervical cancer, and therefore the Food and
			 Drug Administration (FDA) recommends that all women get regular Pap tests. The
			 Pap test looks for cell changes caused by HPV, so the cervix can be treated
			 before the cells turn into cancer. The FDA also states the Pap test can also
			 find cancer in its early stages so it can be treated before it becomes too
			 serious, and reaches the conclusion that it is rare to die from cervical cancer
			 if the disease is caught early.</text>
			</paragraph><paragraph id="H6355ED2EFDD24BB9B07F61AF736243F9"><enum>(3)</enum><text>On June 8, 2006,
			 the FDA approved Gardasil, the first vaccine developed to prevent cervical
			 cancer, precancerous genital lesions, and genital warts due to human
			 papillomavirus (HPV) types 6, 11, 16, and 18. Gardasil is a recombinant
			 vaccine, it does not contain a live virus, and it is given as three injections
			 over a six-month period. The vaccine is approved for use in females 9–26 years
			 of age. However, the FDA also states that since the vaccine is new, more
			 studies need to be done to determine how long women will be protected from HPV.
			 For example, the FDA does not know if a booster is needed after a couple of
			 years to ensure continuity of protection.</text>
			</paragraph><paragraph id="HD70A79D6A8E64E05AC69E6D217BFCB1D"><enum>(4)</enum><text>As detailed by the
			 FDA, four studies were conducted in 21,000 women, one in the United States and
			 three multinational, to show how well Gardasil worked in women between the ages
			 of 16 and 26. The study period was not long enough for cervical cancer to
			 develop; however, preventing cervical precancerous lesions is believed highly
			 likely to result in the prevention of cervical cancer.</text>
			</paragraph><paragraph id="HCB2FB15CCD2448E08FFFC418733E9143"><enum>(5)</enum><text>In January 2007
			 the Advisory Committee on Immunization Practices (ACIP), under the Centers for
			 Disease Control and Prevention, issued changes to the previous childhood and
			 adolescent immunization schedule. The ACIP recommends the new human
			 papillomavirus vaccine (HPV) to be administered in a 3-dose schedule with the
			 second and third doses administered 2 and 6 months after the first dose.
			 Routine vaccination with HPV is recommended for females aged 11–12 years, the
			 vaccination series can be started in females as young as age 9 years, and a
			 catch up vaccination is recommended for females aged 13–26 years who have not
			 been vaccinated previously or who have not completed the full vaccine
			 series.</text>
			</paragraph><paragraph id="H5AE640901D4F4858A74137F2CF98EDF2"><enum>(6)</enum><text>In July 2008
			 Judicial Watch, a Washington-based public interest group, reported that there
			 have been close to 9,000 health complaints as a result of Gardasil. These
			 complaints have surfaced because Gardasil recipients have experienced
			 everything from massive wart outbreaks to paralysis, and even death in 18
			 cases.</text>
			</paragraph><paragraph id="H397C0BAE5AB54BEF8EEDE24722DCB616"><enum>(7)</enum><text>States
			 historically have maintained the practice of applying immunization
			 recommendations to their school admittance policies so as to protect
			 schoolchildren from outbreaks of contagious disease. The Association of
			 American Physicians and Surgeons states that there is no public health purpose
			 for mandating HPV vaccine for schoolchildren. HPV is a sexually transmitted
			 disease.</text>
			</paragraph><paragraph id="H085CF351C00E43E2B583DF9940C3793B"><enum>(8)</enum><text>With a number of
			 states entertaining legislation which takes the unprecedented step in requiring
			 young girls to obtain a vaccine for a disease that is not spread by casual
			 contact in order to attend school, many organizations and associations have
			 come out against mandatory HPV vaccine programs.</text>
			</paragraph><paragraph id="H600D79C2439246398829CE0C3BAD6B37"><enum>(9)</enum><text>The American
			 College of Pediatricians and the Association of American Physicians and
			 Surgeons are opposed to any legislation which would require HPV vaccination for
			 school attendance. They have stated that excluding children from school for
			 refusal to be vaccinated for a disease spread only by intercourse is a serious,
			 precedent-setting action that trespasses on the right of parents to make
			 medical decisions for their children as well as on the rights of the children
			 to attend school.</text>
			</paragraph><paragraph id="H2E4BC47EC83743EEBFFED2B9A71DF140"><enum>(10)</enum><text>Federal funds
			 should not be used to implement a mandatory vaccine program for a disease that
			 does not threaten the public health of schoolchildren in the course of casual,
			 daily interaction between classmates and inserts the government into the lives
			 of children, parents, and physicians.</text>
			</paragraph></section><section id="HCFF0CCED5C474E1C99E299017F734DF8"><enum>3.</enum><header>Prohibition
			 against funding for mandatory human papillomavirus (hpv) vaccination
			 programs</header><text display-inline="no-display-inline">No Federal funds or
			 other assistance may be made available to any State or political subdivision of
			 a State to establish or implement any requirement that individuals receive
			 vaccination for human papillomavirus (HPV).</text>
		</section></legis-body>
</bill>
